Please login to the form below

Not currently logged in
Email:
Password:

Market wants asthma delivery options

The differentiation of new asthma therapies is becoming increasingly challenging, though a new report suggests that the future market will respond positively to means of drug delivery which offer flexibility and choice for patients.

The differentiation of new asthma therapies is becoming increasingly challenging, though a new report suggests that the future market will respond positively to means of drug delivery which offer flexibility and choice for patients.

Combination products for asthma are also growing in popularity, according to research undertaken for a new report, Asthma: Novel Product Differentiation Remains a Key Challenge, produced by international healthcare research and advisory firm, Decision Resources.

"Pulmologists emphasise that delivery device and formulation can influence patient compliance and, in turn, outcomes - as a result, they value a variety of options for their patients,"noted Dr Cindy Mundy, director at the company.

The report spotlights the new formoterol/mometasone bronchodilator combination product in development by Schering-Plough and Novartis, anticipated to gain marketing approval next year. According to the findings, S-P and Novartis may have similar flexibility in terms of delivery options for formoterol/mometasone as does the current market leader, GlaxoSmithKline, for Seretide

The report predicts, however, that 'following its approval, Schering-Plough/Novartis' formoterol/mometasone will become the clinical gold standard for asthma by 2011, owing to its competitive advantages in delivery', adding too that 'urveyed primary care physicians indicated they word prescribe formoterol/mometasone to 34 per cent of their patients with persistent asthma'.

Decision Resources compiles it reports by combining market forecasts with clinical and commercial endpoints. Its market share projections also rely on feedback elicited through prescriber surveys.

Some positive editorial coverage and opinion have been given over to the new combination offering, which could be made available in both dry power inhaler and metered dose inhaler formulations, however the product's two developers have not yet confirmed on plans for its method of administration.

28th January 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics